ProCE Banner Events

Gain Awareness Around Clinical Data in the Adjuvant Treatment of High-Risk Urothelial Carcinoma`

Please join Alan Tan, MD, to gain more awareness around clinical data in the adjuvant treatment of high-risk urothelial carcinoma.

Key Takeaway

  • Opdivo® is the only FDA approved IO agent for adjuvant treatment of adult patients with high-risk muscle-invasive urothelial carcinoma after undergoing radical resection
Time and location

Tuesday, December 10, 2024

12:15 PM - 1:00 PM Pacific Time (PT)

Virtual

Faculty
Alan Tan, MD

GU Medical Oncology Lead
Vanderbilt University
Nashville, Tennessee

Sponsored By

Bristol Myers Squibb

ProCE Banner

Additional Information

OPDIVO® is a registered trademark of Bristol-Myers Squibb Company. All other trademarks are the property of their respective owners.

Opdivo Important Safety Information
Opdivo Full Package Insert

Most common side effects
It’s important to remember that these are not all of the possible side effects of OPDIVO or OPDIVO-based combinations. That’s why you need to report any discomfort or change in the way you are feeling to your healthcare team, even if your symptoms are not listed below. Some of the side effects may be life-threatening and may need your doctor's immediate attention.

These are not all the possible side effects. Talk to your healthcare team or pharmacist for more information. You are encouraged to report side effects of prescription drugs to the FDA. Call 1-800-FDA-1088.

OPDIVO alone

  • Feeling tired
  • Rash
  • Pain in muscles, bones, and joints
  • Itchy skin
  • Diarrhea
  • Nausea
  • Weakness
  • Cough
  • Vomiting
  • Shortness of breath
  • Constipation
  • Decreased appetite
  • Back pain
  • Upper respiratory tract infection
  • Fever
  • Headache
  • Stomach-area (abdominal) pain
  • Urinary tract infection

1506-US-2400738-11/24